Zheng Xueping, Zhang Xu, Liu Xuejun, Mu Wenfeng, Yang Wenru, Liu Youxin, Ge Ping, Li Haifeng
Department of Neurology, The Affiliated Hospital of Qingdao University, China.
Intern Med. 2014;53(20):2377-80. doi: 10.2169/internalmedicine.53.0814. Epub 2014 Oct 15.
Tacrolimus, a novel immunosuppressant agent, has been widely used in organ transplantation and autoimmune diseases. We herein present a case of neuromyelitis optica spectrum disorder (NMOSD) combined with Sjögren's syndrome (SS) successfully treated with tacrolimus. This patient repeatedly presented with recurrent longitudinally extensive transverse myelitis. Her NMO-IgG and anti-SSA and anti-SSB antibodies were seropositive. Considering the frequency of relapses and severe disability, tacrolimus was initiated after failure of intravenous cyclophosphamide. Her status was steady for over 36 months after tacrolimus treatment. This report indicates that tacrolimus may be a potentially effective immunosuppressant for NMOSD with systemic autoimmune diseases.
他克莫司是一种新型免疫抑制剂，已广泛应用于器官移植和自身免疫性疾病。我们在此报告一例视神经脊髓炎谱系障碍（NMOSD）合并干燥综合征（SS）患者，经他克莫司成功治疗。该患者反复出现复发性纵向广泛横贯性脊髓炎。她的NMO-IgG以及抗SSA和抗SSB抗体血清学呈阳性。考虑到复发频率和严重残疾情况，在静脉注射环磷酰胺治疗失败后开始使用他克莫司。他克莫司治疗后，她的病情稳定超过36个月。本报告表明，他克莫司可能是治疗合并全身性自身免疫性疾病的NMOSD的一种潜在有效免疫抑制剂。
